Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wolfgang Ebel

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Annals of the New York Academy of Sciences|December 31, 2005
Morphogenics as a tool for target discovery and drug developmentNicholas C Nicolaides, Wolfgang Ebel, Brad Kline, et al.
Expert Opinion on Drug Discovery|March 16, 2013
Developing novel biopharmaceutical products through morphogenicsNicholas C Nicolaides, Phillip M Sass, Qimin Chao, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 8, 2007
Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migrationBrian Tomkowicz, Katherine Rybinski, Brian Foley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2014
A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumorsLuis A Diaz, Christina M Coughlin, Susan C Weil, et al.
Cancer Immunity|March 10, 2007
Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alphaWolfgang Ebel, Eric L Routhier, Brian Foley, et al.
Cancer Immunity|December 20, 2007
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelinRaffit Hassan, Wolfgang Ebel, Eric L Routhier, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 1, 2006
Human antibodies for immunotherapy development generated via a human B cell hybridoma technologyJian Li, Tao Sai, Marc Berger, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Annals of the New York Academy of Sciences|December 31, 2005
Morphogenics as a tool for target discovery and drug developmentNicholas C Nicolaides, Wolfgang Ebel, Brad Kline, et al.
Expert Opinion on Drug Discovery|March 16, 2013
Developing novel biopharmaceutical products through morphogenicsNicholas C Nicolaides, Phillip M Sass, Qimin Chao, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 8, 2007
Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migrationBrian Tomkowicz, Katherine Rybinski, Brian Foley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2014
A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumorsLuis A Diaz, Christina M Coughlin, Susan C Weil, et al.
Cancer Immunity|March 10, 2007
Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alphaWolfgang Ebel, Eric L Routhier, Brian Foley, et al.
Cancer Immunity|December 20, 2007
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelinRaffit Hassan, Wolfgang Ebel, Eric L Routhier, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 1, 2006
Human antibodies for immunotherapy development generated via a human B cell hybridoma technologyJian Li, Tao Sai, Marc Berger, et al.
Pageof 1